Sutro Biopharma Dividendes et rachats
Dividende contrôle des critères 0/6
Sutro Biopharma n'a pas d'antécédents de versement de dividendes.
Informations clés
n/a
Rendement du dividende
-0.009%
Rendement des rachats
| Rendement total pour l'actionnaire | -0.009% |
| Rendement futur des dividendes | 0% |
| Croissance des dividendes | n/a |
| Prochaine date de paiement du dividende | n/a |
| Date ex-dividende | n/a |
| Dividende par action | n/a |
| Ratio de distribution | n/a |
Mises à jour récentes sur les dividendes et les rachats
Pas de mise à jour
Recent updates
Seeking Alpha • May 01
Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell
Summary Sutro Biopharma underwent major restructuring, including management changes, layoffs, and a 1-for-10 reverse split to maintain NASDAQ compliance. STRO's lead program, STRO-004, is a next-gen tissue factor-targeting exatecan ADC with a DAR of 8, aiming for Phase 1 data in mid-2026. Despite claims of improved safety via Fc-silencing and novel linker chemistry, prior ADCs (luveltamab tazevibulin) with similar strategies suffered high toxicities and discontinuation. Cash reserves and Vaxcyte equity holdings have dropped from ~$400M between 2023 to 2025 to $141.5M as of March 2026, raising sustainability concerns ahead of key clinical readouts. Read the full article on Seeking Alpha
Mise à jour du récit • Apr 25
STRO: ADC Progress And Equity Offering Will Shape Balanced Future Outlook
Analysts have raised their price target for Sutro Biopharma by about $2, reflecting updated fair value estimates along with revised assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Sutro reported promising preclinical data for multiple next generation antibody drug conjugates (ADCs), including STRO-004, STRO-006 and STRO-227, at the American Association for Cancer Research Annual Meeting 2026.Mise à jour du récit • Apr 10
STRO: Equity Offering And Lockup Structure Will Support Future Upside
Analysts now place Sutro Biopharma's price target at about $30.11, up from roughly $27.88. This reflects updated assumptions around fair value, discount rate, future revenue trends, profit margin, and a higher future P/E of about 199x.Mise à jour du récit • Mar 27
STRO: Recent Equity Raises And Lockup Structure Will Support Future Upside
Analysts have revised their price target for Sutro Biopharma from $21.25 to $27.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and a higher future P/E in their models. What's in the News Sutro Biopharma filed a follow-on equity offering of up to US$100 million in common stock as an at-the-market program, providing flexibility to issue shares over time.
Mise à jour du récit • Mar 10
STRO: Equity Raise And Index Removal Will Set Up Future Upside Potential
Analysts have kept their $51.00 price target on Sutro Biopharma unchanged, as a slightly lower discount rate and a higher assumed future P/E multiple are seen as offsetting a softer revenue outlook and reduced profit margin expectations. What's in the News Sutro Biopharma completed a follow on equity offering of approximately US$110.0 million, issuing 7,868,383 common shares at US$13.98 per share with a US$0.8388 discount per share (Key Developments).Mise à jour du récit • Feb 24
STRO: Reverse Split And Equity Raise Will Support Future Upside
Analysts have inched up their price target on Sutro Biopharma to $21.25 from $21, citing updated assumptions that include a slightly lower discount rate, modest changes to long term profit margin expectations, and a higher future P/E multiple. What's in the News Sutro Biopharma completed a follow on equity offering of common stock, raising about US$110.0m through the sale of 7,868,383 shares at US$13.98 per share, reflecting a US$0.8388 per share discount (Key Developments).Mise à jour du récit • Feb 09
STRO: Reverse Split And ADC Pipeline Progress Will Support Future Upside Potential
Analysts have maintained their price target on Sutro Biopharma at US$51.00, making only minor adjustments to their models. Slightly softer assumptions for long-term revenue growth and profit margins are largely offset by a higher future P/E multiple.Article d’analyse • Feb 04
Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Mise à jour du récit • Jan 26
STRO: Reverse Split And ADC Pipeline Progress Will Drive Future Upside
Analysts lifted their price target on Sutro Biopharma to US$51.00 per share, highlighting updated assumptions around fair value, discount rate, revenue growth expectations, profit margins, and a slightly lower future P/E as the key drivers of the change. What's in the News Sutro Biopharma regained compliance with Nasdaq’s continued listing standard for minimum share price under Rule 5450(a)(1) after its common stock maintained an average closing price of at least US$1.00 following a 1:10 reverse stock split effective December 3, 2025 (company announcement).Mise à jour du récit • Jan 10
STRO: Reverse Split And ADC Pipeline Progress Will Support Future Upside
Analysts have trimmed their price target on Sutro Biopharma from US$22.29 to US$21.00, citing updated assumptions that include a slightly lower discount rate, a wider expected revenue decline of about 6.3 percentage points, a modestly higher profit margin, and a higher future P/E multiple. What's in the News Sutro Biopharma was removed from the Nasdaq Biotechnology Index, which can affect index fund ownership that tracks this benchmark (Index Constituent Drops).Article d’analyse • Dec 31
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 46%
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders would be excited to see that the share price has had a great month...Mise à jour du récit • Dec 17
STRO: Reverse Split And ADC Pipeline Focus Will Drive Future Upside
Narrative Update on Sutro Biopharma Analysts have reduced their price target on Sutro Biopharma from approximately $28.00 to about $22.30 per share. This reflects a lower assumed future price to earnings multiple, while expectations for revenue growth and profit margins remain largely unchanged.Mise à jour du récit • Dec 03
STRO: Reverse Split And ADC Focus Will Drive Long-Term Upside
Analysts have raised their price target on Sutro Biopharma from 2.69 dollars to 28.00 dollars, citing expectations for improved long term profit margins despite softer revenue growth assumptions and a modestly higher discount rate. What's in the News Sutro Biopharma approved a 1 for 10 reverse stock split or significant stock dividend effective December 3, 2025, aimed at improving its share price profile for investors (company announcement).Mise à jour du récit • Sep 10
ADC Pipeline Focus Will Advance Preclinical Drug Development
The downward revision in Sutro Biopharma’s price target reflects worsening net profit margin and deeper negative revenue growth forecasts, with fair value decreasing from $3.11 to $2.69. What's in the News Sutro Biopharma entered a collaboration with the FDA to co-develop reference materials and improve regulatory standards for ADC drug development, leveraging Sutro's XpressCF technology and FDA's analytical capabilities.Article d’analyse • Jul 01
Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Article d’analyse • Apr 18
Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet
Unfortunately for some shareholders, the Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price has dived 36% in the last...
Nouveau récit • Apr 03
ADC Pipeline Focus Will Advance Preclinical Drug Development
Strategic focus on preclinical programs and restructuring is set to drive future growth by enhancing drug development and revenue potential.Article d’analyse • Mar 04
Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 25%
To the annoyance of some shareholders, Sutro Biopharma, Inc. ( NASDAQ:STRO ) shares are down a considerable 25% in the...Seeking Alpha • Jan 02
Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless
Summary STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows promising efficacy in ovarian cancer, with manageable toxicity, positioning it for potential Accelerated Approval by mid-2027. Financially, STRO has a two-year runway with current cash reserves, but further financing may be needed, risking shareholder dilution. Casting a wider net in pivotal trials carries risks but could expand patient eligibility, enhancing the overall investment thesis. Read the full article on Seeking AlphaArticle d’analyse • Nov 30
Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge
Unfortunately for some shareholders, the Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price has dived 26% in the last...Article d’analyse • Oct 11
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive
The Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Sep 23
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Summary STRO specializes in ADCs for oncology, leveraging XpressCF and XpressCF+ platforms for precise antibody-drug conjugates without living cells. STRO-002, a promising ADC for ovarian cancer, has shown favorable safety and efficacy in trials, with potential FDA approval by 2026-2027. Collaborations with Merck, Vaxcyte, and Astellas Pharma could generate up to $3 billion in milestone payments. In my view, STRO's valuation appears cheap relative to its potential. It has ample resources to fund operations and research, making it a "strong buy" despite inherent biotech risks. Read the full article on Seeking AlphaArticle d’analyse • Aug 24
There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shares have had a really impressive month, gaining 29% after a shaky period...Article d’analyse • Aug 22
Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts
Celebrations may be in order for Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders, with the analysts delivering a...Article d’analyse • Aug 16
Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results
Sutro Biopharma, Inc. ( NASDAQ:STRO ) defied analyst predictions to release its quarterly results, which were ahead of...Article d’analyse • Jun 26
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Unfortunately for some shareholders, the Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price has dived 28% in the last...Article d’analyse • May 31
We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
Key Insights Sutro Biopharma to hold its Annual General Meeting on 6th of June Salary of US$686.7k is part of CEO Bill...Article d’analyse • Apr 02
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Market forces rained on the parade of Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders today, when the analysts...Article d’analyse • Mar 28
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
With a price-to-sales (or "P/S") ratio of 2x Sutro Biopharma, Inc. ( NASDAQ:STRO ) may be sending very bullish signals...Article d’analyse • Dec 19
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shares have had a really impressive month, gaining 43% after a shaky period...Article d’analyse • Aug 24
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Feb 10
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Jan 12
An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Key Insights Sutro Biopharma's estimated fair value is US$13.8 based on 2 Stage Free Cash Flow to Equity Current share...Stabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de STRO ont été stables dans le passé.
Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de STRO ont augmenté.
Rendement des dividendes par rapport au marché
| Sutro Biopharma Rendement des dividendes par rapport au marché |
|---|
| Segment | Rendement du dividende |
|---|---|
| Entreprise (STRO) | n/a |
| 25% du marché (US) | 1.4% |
| 25% du marché (US) | 4.3% |
| Moyenne du secteur (Biotechs) | 2.4% |
| Analyste prévisionnel (STRO) (jusqu'à 3 ans) | 0% |
Dividende notable: Impossible d'évaluer le rendement des dividendes de STRO par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.
Dividende élevé: Impossible d'évaluer le rendement des dividendes de STRO par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.
Bénéfice distribué aux actionnaires
Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de STRO afin de déterminer si les dividendes versés sont couverts par les bénéfices.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car STRO n'a signalé aucun versement.
Découvrir des entreprises qui versent des dividendes élevés
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 23:43 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Sutro Biopharma, Inc. est couverte par 19 analystes. 12 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Tazeen Ahmad | BofA Global Research |
| Thomas Shrader | BTIG |